Improved Surgical Success of Combined Glaucoma Tube Shunt and Retisert Implantation in Uveitic Eyes: A Retrospective Study by unknown
ORIGINAL RESEARCH
Improved Surgical Success of Combined Glaucoma
Tube Shunt and Retisert Implantation in Uveitic
Eyes: A Retrospective Study
Daniel B. Moore . Sandra Stinnett . Glenn J. Jaffe . Sanjay Asrani
To view enhanced content go to www.ophthalmology-open.com
Received: October 6, 2015 / Published online: November 7, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: The purpose of this study was to
determine whether the outcomes following
placement of a fluocinolone acetonide
implant (Retisert; Bausch & Lomb, Inc.)
combined with an AhmedTM glaucoma valve
(New World Medical, Inc.) in eyes with uveitic
glaucoma (UG Retisert) were different when
compared to an Ahmed valve alone in eyes
with uveitic glaucoma or primary open angle
glaucoma (UG non-Retisert and POAG,
respectively).
Methods: Retrospective, interventional study
of consecutive uveitic and OAG eyes
undergoing Ahmed valve (AV) implantation
with or without combined Retisert
insertion at a single academic center between
2009 and 2012. Surgical success was defined as
intraocular pressure (IOP) between 5 and
18 mmHg and greater than 20% reduction of
IOP at two consecutive visits without need for
additional IOP-lowering medications or surgical
procedures. Secondary outcome measures
included IOP and number of glaucoma
medications.
Results: Sixty eyes of 60 patients (22 UG
Retisert, 16 UG non-Retisert, 22 POAG) were
included. Mean ± standard deviation surgical
success duration was significantly greater in UG
Retisert eyes, 629 ± 53 days, compared to those
with UG non-Retisert, 361 ± 37 days, and
POAG, 472 ± 65 days (P = 0.034). At
24 months, the mean IOP was 11.7, 12.1, and
15.0 mmHg and the average patient was on
1.45, 0.71, and 2.00 medications in the UG
Retisert, UG non-Retisert, and POAG valve
groups, respectively.
Conclusion: Retisert implants when combined
with AV in uveitic glaucoma had a longer
duration of surgical success than uveitic or
POAG treated with AV insertion alone.
Keywords: Uveitis; Glaucoma; Uveitic
glaucoma; Glaucoma drainage device; Retisert;
Ahmed valve
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INTRODUCTION
Secondary glaucoma is a common problem in
eyes with uveitis, and elevated intraocular
pressure (IOP) occurs in 11–46% of eyes with
chronic uveitis [1–4]. Uveitic glaucoma can be
difficult to treat because of the relatively young
mean patient age, diverse pathogenic factors,
prolonged use of topical corticosteroids, and
limited tolerance to medical therapies [5].
Accordingly, many patients ultimately require
glaucoma surgery to achieve long-term stability
[5, 6]. Glaucoma drainage devices are
increasingly becoming the preferred procedure
in these patients [7].
The sustained-release intravitreal
fluocinolone acetonide implant (Retisert;
Bausch & Lomb, Inc., Rochester, NY, USA) was
approved in 2005 by the US Food and Drug
Administration on the basis of two prospective
multicenter randomized pivotal trials to treat
eyes with noninfectious posterior uveitis [8–10].
The Retisert implant produces sustained
intraocular corticosteroid delivery for up to
36 months. However, 70% of the
Retisert-implanted eyes showed susceptibility
to steroid-induced increased IOP and 33.8%
required surgery as reported recently [11]. In
another study, the Retisert-implanted eyes had
about a fourfold risk of developing IOP
elevation of C10 mmHg and incident
glaucomatous optic neuropathy compared
with those assigned to systemic
immunosuppressive therapy for uveitis [12].
Glaucoma drainage devices have been fairly
effective in IOP control in eyes with uveitic
glaucoma [5]. However, in eyes with uveitic
glaucoma requiring treatment with
simultaneous Retisert implant and glaucoma
drainage devices, the long-term IOP control
may be limited due to chronic steroid delivery.
The purpose of this study was to determine the
outcomes of AhmedTM valve implant (New
World Medical, Inc., Rancho Cucamonga, CA,
USA) combined with a Retisert in eyes with
uveitic glaucoma and compare that to results in
eyes with uveitic glaucoma and primary open
angle glaucoma (POAG) treated with an Ahmed
valve implant alone.
METHODS
This study was approved by the Duke University
Institutional Review Board and adhered to the
tenets of the declaration of Helsinki. A
retrospective record review was conducted of
consecutive patients with uveitic glaucoma
evaluated at the Duke Eye Center between
September 2009 and September 2012 in whom
a Retisert implant and Ahmed valve were
inserted at the same surgical session (‘UG
Retisert’ group). Patients underwent Retisert
implantation if either their uveitis was
considered uncontrolled with topical and
systemic immunosuppressive therapy by their
respective surgeon or were intolerant of
systemic immunosuppressive therapy. Of these
eyes, those that had either uncontrolled IOP
([21 mmHg) on maximum tolerated medical
therapy or had a history of a IOP spike following
a previous steroid injection (intravitreal or
posterior subtenon’s) were scheduled to
undergo an Ahmed implant simultaneously.
Similar data were collected from records of
patients seen during the same period with
uveitic glaucoma and POAG (denoted ‘UG
non-Retisert’ and ‘POAG’ groups, respectively).
The eyes in these two groups underwent an
Ahmed implant if they had uncontrolled IOP
on maximum tolerated medical therapy. For all
groups, eyes were excluded if they had
undergone previous surgery to place a
glaucoma drainage device or trabeculectomy
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or if they had undergone previous or concurrent
vitreoretinal surgery. None of the patients in
any group had a pars plana tube. The only prior
intraocular surgery acceptable for inclusion was
cataract extraction.
Data Collection
Baseline and follow-up clinical and
intraoperative data were recorded in an
electronic database. Clinical data collected
included age at surgery, gender, operative eye,
Ahmed valve model, prior or concurrent
cataract extraction, best-corrected Snellen
visual acuity (VA), IOP by applanation
tonometry [either Tono-Pen applanation
(Reichert, Inc., Depew, NY, USA) or Goldmann
applanation (Haag Streit International, Mason,
OH, USA)], systemic immunosuppressive
therapy, use of topical steroids during pre- and
postoperative periods, and number of glaucoma
medications. Measurement points included a
preoperative visit, intraoperative data,
postoperative month one, postoperative
month six, postoperative year one and
postoperative year two.
Statistical Analysis
The primary outcome measure was surgical
success, defined as IOP between 5 and
18 mmHg and greater than 20% reduction of
IOP at two consecutive visits without loss of
light perception, need for additional
IOP-lowering surgical procedure, or removal of
Ahmed valve for any reason. Secondary
outcome measures included the level of IOP,
number of glaucoma medications and
best-corrected VA (BCVA) converted to the
logarithm of the minimum angle of resolution
(logMAR) units.
Descriptive statistics were computed at each
time point for IOP (mmHg), number of
medications, and VA (logMAR). Differences in
means among and between groups were
assessed using analysis of variance and the
unpaired t test, respectively. Changes from
baseline to postoperative values were assessed
using the paired t test. Surgical success duration
was compared among the three groups using
Kaplan–Meier curves and the log-rank test. Data
analysis was completed using SAS Statistical
Analysis, version 9.3 (Cary, NC, USA).
RESULTS
Preoperative Characteristics
A total of 60 eyes of 60 patients were included in
the study. Simultaneous combined Retisert
implantation and Ahmed valve placement was
performed on 22 uveitic eyes. Ahmed valve
alone was performed on 16 uveitic eyes and 22
POAG eyes during the study period. Baseline
demographics and implant model are presented
in Table 1. Fifty-nine percent of UG Retisert eyes
underwent simultaneous cataract extraction,
compared to 25% and 14% in the UG
non-Retisert and POAG groups, respectively.
The Retisert implant was performed by three
vitreoretinal surgeons and the Ahmed implants
were performed by four glaucoma surgeons. Of
note, there was a significant difference in mean
ages in the three groups (P\0.001) and all
pair-wise comparisons of age between groups
were also significantly different (P\0.006). Of
the eyes in the UG Retisert group, 11 were on no
systemic immunotherapy. Of the remaining 11
eyes that were on systemic immunosuppressive
therapy, 7 stopped such therapy following the
Retisert implant and 4 were continued on such
therapy for systemic reasons. Such therapy
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included medications such as methotrexate,
oral prednisone, hydroxychloroquine,
etanercept, and mycophenolate mofetil. Only
one of the eyes of the UG non-Retisert group
was being treated with oral immunosuppressive
therapy, which was continued postoperatively.
All the eyes in both the UG Retisert and UG
non-Retisert groups were on varying doses of
topical prednisolone prior to surgery and were
continued on a slow tapering schedule till
Table 1 Preoperative demographics and characteristics
Characteristic Uveitic–Retisert
valve n5 22
Uveitic valve n5 16 POAG valve n5 22
Age (years), mean ± SDa 44.3 ± 20.0 51.0 ± 12.0 68.3 ± 12.2
Gender, n (%)
Male 7 (32) 10 (63) 12 (54)
Female 15 (68) 6 (38) 10 (45)
Ahmed valve model, n (%)
S2 6 (27) 9 (56) 9 (41)
S3 1 (5) 0 (0) 0 (0)
FP7 10 (45) 7 (44) 13 (59)
M4 5 (23) 0 (0) 0 (0)
Prior CE/IOL, n (%) 9 (41) 14 (52) 10 (45)
Concurrent CE/IOLb 13 (59) 4 (25) 3 (14)
Preop IOP (mmHg)
Mean (SD) 26.73 (11.84) 32.53 (10.91) 29.25 (10.07)
Range 13–50 13–50 17–56
Number of medications
Mean (SD) 2.82 (0.66) 3.25 (0.77) 2.86 (1.12)
Range 2–4 2–4 0–5
BCVA (logMAR)
Mean (SD)c -1.17 (0.78) -0.63 (0.67) -0.76 (0.82)
Range (-3)–(-0.18) (-2.3)–0 (-2.6)–0
Follow-up (days)
Mean (SD) 434 (291) 576 (254) 511 (298)
Range 30–720 181–978 30–1023
BCVA best-corrected visual acuity, CE/IOL cataract extraction with intraocular lens placement, IOP intraocular pressure,
POAG primary open angle glaucoma, SD standard deviation
a Mean age signiﬁcantly different among groups (P\0.001, Kruskal–Wallis test)
b Concurrent CE/IOL signiﬁcantly different among the uveitic Retisert compared to uveitic and POAG valve groups
(P = 0.036 and 0.0017, respectively, t test)
c Mean logMar visual acuity of uveitic–Retisert group signiﬁcantly less than uveitic group (P = 0.021, t test)
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discontinuation 8–10 weeks after the surgery.
Six eyes of each of these groups remained on
either once or twice a day of chronic
postoperative topical prednisolone therapy.
However, none of the eyes of the POAG group
received steroids preoperatively and all stopped
topical steroids 4–5 weeks post-surgery. The
mean preoperative IOP was significantly
higher in the UG non-Retisert group
(32.5 mmHg) compared to the POAG group
(29.2 mmHg, P = 0.024). Preoperative IOP was
similar in the UG non-Retisert and UG Retisert
(26.7 mm Hg) groups (P = 0.643). All eyes were
typically on three glaucoma medications prior
to surgery in all groups. The mean logMAR
preoperative BCVA was significantly worse in
the UG Retisert group (-1.17) as compared to
both the uveitic valve and POAG valve groups
(-0.63 and -0.76, respectively; P = 0.005 and
P = 0.017, respectively).
Surgical Success
By Kaplan–Meier survival analysis, there was a
significant difference in the duration of
surgical success among the UG Retisert
compared to both the UG non-Retisert and
POAG groups (P = 0.034). The mean surgical
success duration was greater in the UG Retisert
group (629 ± 53 days) compared to the UG
non-Retisert (361 ± 37 days) and the POAG
valve (472 ± 65 days) groups. The cumulative
probability of success at 1 year was 84%, 63%,
and 61% for the UG Retisert, UG non-Retisert,
and POAG groups, respectively. The
cumulative probability of success at 2 years
was 67%, 54%, and 27% in the UG Retisert,
UG non-Retisert, and POAG groups,
respectively (Fig. 1). The predominant cause
of failure in all groups was inadequate IOP
control due to an IOP[18 mmHg or less than
20% reduction in IOP (Table 2). Success
duration was not significantly different
among different models of the Ahmed valve
(FP7, M4, S2, or S3; P = 0.633, log-rank test).
No complications associated with Retisert
implantation were noted in this study.
Postoperative Intraocular Pressure
At 24 months postoperatively, the average IOP
was 11.7, 12.1, and 15.0 in the UG Retisert, UG
non-Retisert, and POAG groups, respectively.
There was a trend towards significance when
comparing the UG Retisert and POAG groups
(P = 0.076) and achieving significance between
the UG non-Retisert and POAG groups
(P = 0.020). The difference in postoperative
IOP between the two uveitic groups was not
significant. In all three groups, the mean IOPs at
all postoperative visits were significantly
reduced compared to the preoperative IOP
(P\0.01 at all time points). The difference in
IOP change between the two uveitic groups was
not significant (Fig. 2). There was no significant
difference in IOP or change in IOP when
comparing uveitis anatomical location or
etiology (P = 0.161–0.923).
Fig. 1 Kaplan–Meier cumulative probability curve of
surgical success for the UG Retisert compared to the
UG non-Retisert and POAG groups. POAG primary open
angle glaucoma
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Medications
The number of glaucomamedications decreased
significantly from baseline in all groups at all
postoperative visits (P\0.018 at all points),
with the exception of the POAG group at
24 months (P = 0.1). At 24 months, the
average patient was on 1.45, 0.71, and 2.00
medications in the UG Retisert, UG
non-Retisert, and POAG groups, respectively.
There were fewer medications administered to
eyes in the UG non-Retisert group as compared
to the POAG group at 12 and 24 months
postoperatively (P = 0.033, 0.058, respectively).
There were no significant differences in the
number of medications used in the UG
non-Retisert and UG Retisert groups (P = 0.542
and 0.626 at 12 and 24 months; Fig. 3).
Visual Acuity
There were no significant changes in
postoperative visual acuities in the UG
non-Retisert and POAG groups at the
Table 2 Causes of Ahmed valve failure
Glaucoma category Uveitic–Retisert
valve (n5 5)
Uveitic valve (n5 5) POAG valve (n5 11)
Inadequate control of IOP 3 (60) 4 (80) 11 (100)
Loss of light perception 1 (20)a
Hypotony 1 (20)
Additional IOP-lowering procedure 1 (20)
Values are presented as n (%)
IOP intraocular pressure, POAG primary open angle glaucoma











0 5 10 15 20 25
Month
Group UG Retisert UG Non-Retisert POAG
Fig. 2 Change in IOP from preoperative (month 0) to postoperative month 24. Each error bar is constructed using 1
standard error from the mean. IOP intraocular pressure, POAG primary open angle glaucoma
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postoperative visits as compared to baseline.
However, the UG Retisert group obtained a
significant improvement in VA at all time
points (P\0.037) likely due to the fact that
59% of UG Retisert eyes underwent
simultaneous cataract extraction, compared to
25% and 14% in the UG non-Retisert and POAG
groups, respectively.
DISCUSSION
This study was designed as a retrospective series
to evaluate the outcomes of Ahmed valve with
or without combined simultaneous Retisert
implantation in eyes with uveitic glaucoma
and to compare the results to Ahmed valve in
eyes with POAG. We found that (1) Retisert
combined with simultaneous Ahmed valve
implantation led to significantly longer success
compared to Ahmed valve alone in eyes with
uveitis or POAG; (2) Retisert combined with
Ahmed valve did not lead to significant
worsening of glaucoma control as suspected
due to prolonged steroid release in uveitic eyes;
and (3) eyes with uveitis had significantly better
IOP control and needed fewer glaucoma
medications following Ahmed valve than eyes
with POAG.
Topical corticosteroids are well known to
improve success in trabeculectomy surgery
because they inhibit fibroblast proliferation,
phagocytosis, and vascular permeability, and
suppress the release of cytotoxic enzymes,
growth, and chemotactic factors [13]. Several
smaller series also suggest positive results with
either preoperative or intraoperative
subconjunctival steroid injection during
trabeculectomy [14–16]. However, the role of
steroids in the management of glaucoma
drainage devices has not been well evaluated.
In one study, intravitreal injection of
triamcinolone acetonide in neovascular
glaucoma did not improve the long-term
success of the Ahmed valve [17]. In another
recent small prospective randomized controlled
trial, patients received intracameral
triamcinolone at the end of either a












0 5 10 15 20 25
MONTH
Group UG Retisert UG Non-Retisert POAG
Fig. 3 Change in number of glaucoma medications (GTTS) from preoperative (month 0) to postoperative month 24. Each
error bar is constructed using 1 standard error from the mean. POAG primary open angle glaucoma
Ophthalmol Ther (2015) 4:103–113 109
surgery [18]. The authors did not find any
significant differences in IOP between groups
at 6 months nor any differences in failure rate.
However, the authors included three different
types of glaucoma drainage devices in the study
and did not analyze the drains separately from
trabeculectomy. Further, the authors did not
provide specific data on enrolled secondary
glaucoma patients, including those with
uveitic glaucoma.
Retisert implantation as a sole procedure has
been well known to lead to elevated IOP as a
complication [11, 12, 19]. However, we
hypothesized that when combined with a
glaucoma drainage device, the corticosteroids
released by the Retisert into the vitreous cavity
transit into the anterior chamber and through
the glaucoma tube implant, thereby internally
modifying the capsule surrounding the
glaucoma implant plate and improving the
surgical success rate. This could be due to a
very low dose of sustained steroid delivery that
perfuses the tissue around the plate, thus
preventing the formation of a dense
collagenous impervious capsule (which likely
contributes to the hypertensive phase or failure
of the Ahmed valve). Some small case series
have also indicated that results are favorable in
eyes with concurrent placement of glaucoma
tube shunts and Retisert implants [20, 21]. The
results of our study further support the role of
combined Retisert and glaucoma tube
implantation in selected eyes with uveitic
glaucoma.
The literature supports the success of
glaucoma drainage devices in uveitic
glaucoma, with cumulative probability of
success of 77–94.4% at 1 year and 50–80% at
2–4 years following Ahmed valve implantation,
as assessed by Kaplan–Meier analysis [5, 22, 23].
The probability of success in our study was 84%
at 1 year and 63% at 2 years in the UG Retisert
and 63% at 1 year and 54% at 2 years in the UG
non-Retisert groups. Though our results are
similar to the reported series, there is no
standard definition of success and different
criteria have been used. The definition used in
the current study combined both IOP reduction
and complications. There are also reports of
other types of glaucoma drainage devices in
uveitic glaucoma, including four small series
evaluating Molteno implants (Molteno
Ophthalmic Limited, Dunedin, New Zealand)
in uveitic patients that found survival estimates
between 80% and 95% at 27–48 months of
follow-up [24–27]. A small retrospective study
of Baerveldt implantation (Abbott Laboratories
Inc. Abbott Park, IL, USA) in uveitic eyes found
cumulative life-table success rates were 95.8% at
3 months and 91.7% at 6–24 months [28].
However, another retrospective series
evaluating the IOP results following Ahmed
valve placement in uveitic as compared to
POAG patients found significantly lower IOP
in the uveitic group at 1 and 2 months, but no
difference at 3–24 months; there was no
significant difference in the cumulative success
rates between the groups [29].
There are some possible explanations for the
finding that uveitic eyes had lower IOP and
fewer medications following glaucoma tube
implant than those with POAG. Endogenous
prostaglandin release plays a complex and
poorly understood role in both uveitis and IOP
[30], and may facilitate some of the success. It is
also possible that uveitic eyes have long-term
postoperative reduced aqueous production,
although no known confirmatory literature
exists.
The preoperative logMar BCVA was
significantly worse in the UG Retisert group as
compared to the other two, owing largely to the
relative degree of media opacity and macular
cystoid edema in this group. Fifty-nine percent
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of eyes in this group underwent simultaneous
cataract extraction thus explaining the
significantly improved BCVA postoperatively.
Limited published data on cataract extraction in
uveitic glaucoma patients or patients with prior
tube shunts suggest possible short-term
influence on IOP but no difference at 1–2 years
[31, 32].
This study has several important limitations.
It is retrospective, not randomized, and covers a
relatively short study period. Since the Retisert
implant typically releases steroid for
approximately 3 years [20, 33], a longer term
study that lasts 5 years might provide
significant additional information. Uveitic
glaucoma is a heterogeneous group of many
inflammatory glaucoma etiologies and
anatomic locations, which limits direct
comparison among and between groups. There
was a preoperative significant difference in IOP
between the UG non-Retisert and POAG groups,
representing a limitation in sample size. The
choice to insert a Retisert implant was at the
surgeon’s discretion, creating the potential for
selection bias. Systemic immunosuppressive
therapy was used preoperatively in the
treatment of half the eyes in the UG Retisert
group (11/22 eyes), which may have had an
influence on the overall outcome of this group;




This retrospective study found that Retisert
combined with Ahmed valve in eyes with
uveitic glaucoma resulted in longer surgical
success compared to eyes with uveitic
glaucoma or POAG treated with Ahmed valve
insertion alone. Eyes with uveitic glaucoma had
better IOP control and were on fewer
medications following Ahmed valve placement
than eyes with POAG. These data should
compel further investigation to elucidate a
reason for the differential response between
groups, and if validated, would support
prospective trials evaluating the expanded use
of steroid implants in selected uveitic
glaucomatous eyes undergoing drainage device
placement.
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